News | March 15, 2012

Devicor Enters Mammotome Distribution Agreement With Carbon Medical

Devicor Enters Mammotome Distribution Agreement With Carbon Medical

March 15, 2012 — Devicor Medical Products Inc. announced that it signed a distribution agreement with Carbon Medical Technologies Inc. Under the agreement Devicor, parent company of Mammotome, will have exclusive rights to market a new beta-glucan tissue marker developed by Carbon Medical Technologies. Financial terms of the agreement were not disclosed.

The new marker will be used in breast biopsies to mark soft tissue at the diagnostic site. The unique design and proprietary material of the product allows for enhanced visibility in all imaging modalities.

"Doctors have told us that consistent and long-lasting visibility under ultrasound and other imaging modalities is important for the treatment of their patients. We believe this product provides that solution," says Tom Daulton, CEO of Devicor and Mammotome.

"We are pleased to partner with Devicor and believe that our work has resulted in a clinically important marker product," says Dean Klein, president and CEO of Carbon Medical Technologies.

Mammotome, the worldwide leader of biopsy site markers and vacuum-assisted biopsy devices, sells products in nearly 50 countries around the world. In addition to this new device, the Mammotome family of marker products, which is used in the diagnosis of breast disease, includes MammoMARK, CorMARK and MicroMARK II.

"Devicor is making tremendous progress toward our goal of building a global medical device business. Our agreement with Carbon Medical Technologies is another example of how our company is investing in innovative products that help clinicians more effectively diagnose and treat patients," says Daulton.

For more information:

Related Content

Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...
Novarad Debuts NovaMG-Pro Mammography Software at RSNA 2018
News | Mammography Reporting Software | November 25, 2018
Novarad Corp. announced new mammography software NovaMG-Pro, specifically for multimodality radiologists that read...
Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA
News | Mammography | November 21, 2018
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological...
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...